Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment.
Li ZhouMin CaoHaibin ZhuZhihong ChiChuanliang CuiXinan ShengLili MaoBin LianBixia TangXieqiao YanXue BaiXuan WangSiming LiJun GuoYing-Shi SunLu SiPublished in: The oncologist (2024)
A delta TGR exceeding 100 best identified HPD patients in the advanced melanoma population treated with anti-PD-1 monotherapy. Hyperprogression was notably prevalent in mucosal melanoma patients with multiple metastatic organs. Caution against HPD is warranted when applying anti-PD-1 monotherapy in mucosal subtype.
Keyphrases
- combination therapy
- end stage renal disease
- newly diagnosed
- open label
- ulcerative colitis
- skin cancer
- ejection fraction
- squamous cell carcinoma
- chronic kidney disease
- small cell lung cancer
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- patient reported outcomes
- basal cell carcinoma
- replacement therapy